Table 2.
Hematologic and Renal responses to HCT
| Bortezomib induction | No Induction | P Value | |
|---|---|---|---|
| Hematologic response at 100 days | 0.01a | ||
| CR | 53 (18) | 29 (20) | |
| PR | 136 (46) | 54 (37) | |
| NR/SD | 53 (18) | 43 (29) | |
| Prog | 5 (2) | 5 (3) | |
| Not evaluable* | 8 (3) | 6 (4) | |
| Missing | 39 (13) | 9 (6) | |
| Best hematologic response | 0.13a | ||
| CR | 107 (36) | 57 (39) | |
| PR | 128 (44) | 49 (34) | |
| NR/SD | 35 (12) | 25 (17) | |
| Prog | 2 (1) | 4 (3) | |
| Not evaluable* | 8 (3) | 6 (4) | |
| Missing | 14 (5) | 5 (3) | |
| Renal response at 100 days | 0.06a | ||
| CR | 50 (17) | 21 (14) | |
| NR/SD | 91 (31) | 61 (42) | |
| Prog | 9 (3) | 8 (5) | |
| Not evaluable* | 8 (3) | 6 (4) | |
| Missing | 136 (46) | 50 (34) | |
| Best renal response | 0.63a | ||
| CR | 99 (34) | 57 (39) | |
| NR/SD | 84 (29) | 40 (27) | |
| Prog | 5 (2) | 3 (2) | |
| Not evaluable* | 8 (3) | 6 (4) | |
| Missing | 98 (33) | 40 (27) |
*
Non-evaluable were patients who died in the first 100 days after transplant.